AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow purchase articles
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Get other permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Quigley, R. B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Quigley, R. B
Related Collections
Right arrow Ethics
Right arrow Health Law
Right arrow Health Policy
Right arrow Immunization/Vaccines
Right arrow Prevention
Right arrow Government
June 2004, Vol 94, No. 6 | American Journal of Public Health 943-947
© 2004 American Public Health Association

VACCINES, UNCERTAINTIES, AND ETHICAL CHALLENGES

Uncertain Benefit: The Public Policy of Approving Smallpox Vaccine Research

Rosemary B Quigley, JD, MPH

The author is with the Baylor College of Medicine, Houston, Tex.

Correspondence: Requests for reprints should be sent to Rosemary B. Quigley, One Baylor Plaza, IREL 401, Houston, TX 77030 (e-mail: rquigley{at}bcm.tmc.edu).

ABSTRACT

Without an accurate assessment of the prospect of bioterrorist attack, it is especially challenging to evaluate the protocols for testing smallpox vaccines in the pediatric population. Usual regulatory mechanisms cannot shepherd research protocols with benefits that can only be characterized as "uncertain" in the face of more than minimal risk.

When a protocol is placed in a government forum for analysis, the public has a unique opportunity to debate the balancing of research risks and benefits on behalf of children who are unable to assent to research themselves, as well as to express views about vaccination policy broadly. This model for review of pediatric research that may be without benefit will be especially important as challenging studies of various vaccines against a range of infectious properties, such as anthrax and severe acute respiratory syndrome (SARS), emerge.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Public Health Association